Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in Severe IgE-mediated Asthma
NCT01912872Phase 4Terminated
- Sponsor
- Novartis
- Start
- Nov 2013
- Primary completion
- Aug 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of omalizumab in IgE-mediated asthma, sponsored by Novartis. Started Nov 2013; status: terminated.
02
Drugs
omalizumab
03
Conditions
IgE-mediated asthma
Beyond the preview
Go deeper on NCT01912872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01912872.